Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893437 | 0.88 | ADORA1 (0.35) | ADORA1 | |
| SCHEMBL4958897 | 0.87 | ADK (0.39) | — | |
| SCHEMBL263892 | 0.86 | ADORA1 (0.41) | ADORA1 | |
| SCHEMBL4317020 | 0.74 | ADORA1 (0.40) | ADORA1 | |
| SCHEMBL769262 | 0.70 | ADORA1 (0.45) | ADORA1 | |
| SCHEMBL5063261 | 0.70 | TSHR (0.43) | — | |
| SCHEMBL574712 | 0.68 | ADORA1 (0.39) | ADORA1 | |
| SCHEMBL1115485 | 0.67 | ADORA1 (0.39) | ADORA1 | |
| SCHEMBL5245060 | 0.67 | ADORA1 (0.38) | ADORA1 | |
| SCHEMBL8329378 | 0.66 | ADORA1 (0.44) | ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4158010-A1 | METHODS FOR STABLE GENOMIC INTEGRATION IN RECOMBINANT MICROORGANISMS | BioPlx, Inc. (US) | 2023-04-05 | — | — | EP | claimed |
| US-20220288135-A1 | LIVE BIOTHERAPEUTIC COMPOSITIONS AND METHODS | BioPlx, Inc. (US) | 2022-09-15 | — | — | US | claimed |
| EP-3996510-A2 | LIVE BIOTHERAPEUTIC COMPOSITIONS AND METHODS | BioPlx, Inc. (US) | 2022-05-18 | — | — | EP | claimed |
| US-20220025364-A1 | METHODS FOR STABLE GENOMIC INTEGRATION IN RECOMBINANT MICROORGANISMS | COMMENSE BIO, INC. | 2022-01-27 | — | — | US | claimed |
| WO-2021007341-A2 | LIVE BIOTHERAPEUTIC COMPOSITIONS AND METHODS | BioPlx, Inc. (US) | 2021-01-14 | — | — | WO | claimed |
| EP-3720458-A1 | METHODS AND COMPOSITIONS TO PREVENT MICROBIAL INFECTION | BioPlx, Inc. (US) | 2020-10-14 | — | — | EP | claimed |
| WO-2019113096-A1 | METHODS AND COMPOSITIONS TO PREVENT MICROBIAL INFECTION | BioPlx, Inc. (US) | 2019-06-13 | — | — | WO | claimed |
| US-20190169623-A1 | METHODS AND COMPOSITIONS TO PREVENT MICROBIAL INFECTION | COMMENSE BIO, INC. | 2019-06-06 | — | — | US | claimed |
| EP-2601209-A1 | GENOMICS OF ACTINOPLANES UTAHENSIS | Bayer Intellectual Property GmbH (DE) | 2013-06-12 | — | — | EP | claimed |
| WO-2012016960-A1 | GENOMICS OF ACTINOPLANES UTAHENSIS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-09 | — | — | WO | claimed |
| WO-2009128644-A9 | GENOME-SCALE BUTANOL-PRODUCING MICROORGANISM METABOLIC NETWORK MODEL AND METHODS USING THE SAME FOR ANALYSIS OF METABOLIC CHARACTERISTICS OF BUTANOL-PRODUCING MICROORGANISMS AND FOR SCREENING DELETION TARGETS | 한국과학기술원 (KR) | 2010-04-15 | — | — | WO | claimed |
| WO-2009128644-A2 | GENOME-SCALE BUTANOL-PRODUCING MICROORGANISM METABOLIC NETWORK MODEL AND METHODS USING THE SAME FOR ANALYSIS OF METABOLIC CHARACTERISTICS OF BUTANOL-PRODUCING MICROORGANISMS AND FOR SCREENING DELETION TARGETS | 한국과학기술원 (KR) | 2009-10-22 | — | — | WO | claimed |
| US-20260085292-A1 | MINIMAL ESSENTIAL MEDIA FOR THE CULTURE OF HUMAN INDUCED PLURIPOTENT STEM CELLS | UNIV NORTHWESTERN (US) | 2026-03-26 | — | — | US | disclosed |
| US-12460204-B2 | Artificial nucleic acid molecules for improved protein or peptide expression | CureVac SE (DE) | 2025-11-04 | — | — | US | disclosed |
| US-20250295749-A1 | INACTIVATED STAPHYLOCOCCUS COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | BIOLOGICAL MIMETICS INC (US) | 2025-09-25 | — | — | US | disclosed |
| EP-4584365-A2 | MINIMAL ESSENTIAL MEDIA FOR THE CULTURE OF HUMAN INDUCED PLURIPOTENT STEM CELLS | Northwestern University (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2000065062-A9 | GENOME SEQUENCE AND POLYPEPTIDES OF PYROCOCCUS ABISSY, FRAGMENT AND USES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2002-09-06 | — | — | WO | disclosed |
| EP-1196583-A2 | TYPE II DNA POLYMERASE FROM PYROCOCCUS ABYSSI | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2002-04-17 | — | — | EP | disclosed |
| WO-2000046405-A9 | METHODS FOR IDENTIFYING DRUG TARGETS BASED ON GENOMIC SEQUENCE DATA | PALSSON BERNHARD (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2000065062-A2 | GENOME SEQUENCE AND POLYPEPTIDES OF PYROCOCCUS ABISSY, FRAGMENT AND USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085292-A1 | MINIMAL ESSENTIAL MEDIA FOR THE CULTURE OF HUMAN INDUCED PLURIPOTENT STEM CELLS | SLC7A11, GLUL, KCNN2 | ADORA1 2270/4885 |
| US-12460204-B2 | Artificial nucleic acid molecules for improved protein or peptide expression | RNMT, NSUN3, RNGTT | ADORA1 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.